13 results about "Rifamycins" patented technology

The invention discloses a fermentation medium for preparing rifamycin O and a fermentation method, and belongs to the field of microbial fermentation. Specifically, the invention discloses a culture medium for preparing rifamycin O. By optimizing the formula and composition of the culture medium and adding beta-cyclodextrin into the culture medium, the titer level of a 50L fermentation tank can be increased to 1830mg / L; the process is further optimized, dissolved oxygen is controlled in stages in the fermentation process, pure oxygen is intermittently introduced, and the fermentation level of a 50L fermentation tank can be increased to 5541 mg / L. According to the method, rifamycin O is obtained through one-step direct fermentation, the fermentation process is simple and controllable, and method support is provided for industrial production.

With respect to a pharmaceutical composition for nasal administration containing a pharmaceutical active ingredient targeting the brain, the purpose of the present invention is to provide: a formulation prescription design, which improves the adhesion efficiency to an olfactory region in the nasal cavity; and a formulation prescription for improving the bioavailability of resveratrol. The composition for nasal administration, which is a particulate composition, contains particles containing (A) a pharmaceutical active ingredient targeting the brain and (B) a binder. By designing the average particle diameter of the particles to 15-30 μm, the amount of adhesion to the olfactory region relative to the amount of adhesion to the concha region in the nasal cavity can be remarkably improved. By adding (A1) rifamycin to a nasal administration composition containing (A2) resveratrol, the bioavailability of the component (A2) can be improved.

This invention relates to novel uses of pharmaceuticals, particularly the use of rifamycin in the preparation of medicaments for treating colorectal cancer. The application described herein involves rifamycin stabilizing the binding of DHRS4 and LONP2 within the mitochondria of colorectal cancer cells, promoting TFAM degradation, thereby impairing mitochondrial biogenesis and function, and inhibiting mitochondrial activity. In this application, rifamycin is either the sole active ingredient or used in combination with other drugs.

This invention discloses a method for preparing rifamycin O, an intermediate of rifaximin, in the field of organic synthesis. The method uses rifamycin B as a starting material, and rifamycin O is obtained by oxidative coupling under the action of a solvent and a catalyst; the catalyst is a FeCl3 / Al2O3 solid oxidant. This invention uses FeCl3 / Al2O3 solid oxidant to oxidize rifamycin B to prepare rifamycin O. The oxidative coupling reaction conditions are mild, the post-processing is simple, the process cycle is short, and the yield and product purity are high, making it suitable for industrial production.

The utility model relates to the technical field of chemical equipment, and discloses an efficient DMF (Dimethyl Formamide) recovery device in a triformyl rifamycin SV production process, which comprises a distillation retort and a rectifying tower, an air outlet pipe is arranged at the top of the distillation retort, an input pipe is arranged at the upper part of the side surface, an output pipe is arranged at the lower part of the side surface, and a heating pipe is arranged at the bottom of the distillation retort; a liquid inlet pipe is arranged on the upper portion of the side face of the rectifying tower, a gas inlet pipe and a liquid discharge pipe are arranged on the lower portion of the side face of the rectifying tower, an exhaust pipe is arranged on the top of the rectifying tower, the liquid inlet pipe is connected with a spraying disc, a plurality of distributors are arranged in the rectifying tower, and PH detection probes and dosing pipes are arranged on the upper portions of the two sides of the distributors. According to the DMF recovery device, the effects of recovering DMF and enabling the purity of the DMF to meet the production requirement are achieved by combining a reduced pressure distillation and rectification segmented operation technology and a pH value adjusting means, the cyclic utilization of resources is realized, the cost of raw materials is reduced, the consumption of the DMF is reduced, the discharge amount of harmful substances in wastewater is reduced, and the environmental protection treatment pressure of enterprises is reduced.

The utility model belongs to the technical field of rifamycin production, and particularly relates to a dosing stirring tank for rifamycin production, which comprises an outer stirring component arranged on a support, the outer stirring component is connected with the stirring tank, an inner stirring component is arranged on the stirring tank, the inner stirring component comprises an inner stirring mechanism and a wall scraping mechanism, and the inner stirring mechanism is connected with the wall scraping mechanism. The outer stirring assembly enables the whole stirring tank to rotate, the inner stirring mechanism stirs materials in the tank, the mixing degree of the materials is greatly improved through the internal and external combined stirring mode, drugs and raw materials are fully reacted, the production quality and efficiency of rifamycin are improved, and the materials are prevented from being attached; according to the rifamycin stirring tank, materials attached to the inner wall of the stirring tank can be scraped off in time, material waste is avoided, meanwhile, normal operation and the service life of the stirring tank are guaranteed, the structure is reasonable, all assemblies are tightly connected and matched, design is scientific and reasonable, operation and maintenance are convenient, and the requirement for modern rifamycin production can be met.

The present invention relates to a solid composition comprising nanoparticles of rifamycin, such as rifapentine, dispersed in a matrix comprising a first excipient and a second excipient. The invention also relates to microneedle arrays, implantable rods, aqueous dispersions and pharmaceutical compositions obtained from said solid compositions as well as their uses.

The invention relates to a new topical nasal pharmaceutical composition for the treatment and prophylaxis of Rhinosinusitis (RS), comprising a homogeneous aqueous suspension with a therapeutically effective amount of the following well-known active ingredients: Rifamycin, an antibiotic and anti-inflammatory agent for topical or local use; fluticasone propionate, an anti-inflammatory agent for local use; optionally, oxymetazoline hydrochloride, a decongestant; and bacterial antigens, local immunostimulants; 0.9% saline solution, a vehicle; and pharmaceutically acceptable excipients q.s., which are formulated for topical administration via nasal spray. The combination of these compounds produces synergy, resulting in a greater local antibiotic, anti-inflammatory, decongestant and immunomodulatory effect at the specific site of action. Its effectiveness in chronic rhinosinusitis is particularly notable in low doses. So is its good tolerance, absence of adverse effects, and ease of application. No rebound congestion has been reported with prolonged use.

The present disclosure relates to compositions comprising rifamycin SV and their use in the treatment of sarcopenia. More specifically, the present disclosure describes pharmaceutical compositions comprising rifamycin SV for use in the treatment of sarcopenia in a subject suffering from a chronic disease.

The present application provides an ointment of a rifamycin-quinolizinone coupling molecule. The components of the ointment of rifamycin-quinolizinone coupling molecule comprise, based on the total mass percentage of 100%, 0.05%-0.7% by mass of the rifamycin-quinolizinone coupling molecule, 55%-65% by mass of polyethylene glycol 400, 25%-35% by mass of polyethylene glycol 3350, 8%-12% by mass of propylene glycol, 0.1%-1% by mass of a solubilizer, and 0.3%-1% by mass of an antioxidant. The ointment of rifamycin-quinolizinone coupling molecule can improve the drug loading capacity of the preparation and the stability of the medicament components, thereby improving the medication effect and user experience.

The application discloses a method for continuously electrochemically synthesizing rifamycin S from rifamycin SV at a microscale, wherein filtrate containing rifamycin SV is pumped into a micro-flow field electrochemical reactor for reaction, and rifamycin S is obtained after acidification and crystallization of the reaction solution. The micro-flow field electrochemical reactor uses a modified graphite comb structure as an anode and an iron comb structure as a cathode, and the modified graphite comb structure and the iron comb structure are crossed to form an electrochemical micro-reaction channel. The surface of the modified graphite comb electrode is obtained by modification on the surface of a common graphite comb electrode. The method can avoid the use of exogenous oxidants and organic extraction reagents, effectively improve the reaction conversion rate, greatly shorten the reaction time, and is simple, safe and stable, and can save the post-treatment cost and is more green and efficient.

The invention discloses a method for preparing rifaximin intermediate rifamycin O. The method comprises the following steps: taking rifamycin B as an initial raw material, taking a continuous flow separation type electrolytic cell as an electroreactor, adopting an ion exchange membrane to isolate a cathode electrolyte and an anode electrolyte, taking the cathode electrolyte as an alkaline solution, and carrying out electrochemical oxidation to prepare the rifaximin intermediate rifamycin O. The method comprises the following steps: preparing a cathode liquid storage chamber and an anode liquid storage chamber, pumping the cathode liquid storage chamber and the anode liquid storage chamber into the anode liquid storage chamber by adopting a circulating pump, ensuring the continuous flow of the solution in the electrolysis process, carrying out electrochemical oxidation reaction at the temperature of 0-100 DEG C and the current of 1-100mA / cm < 2 >, carrying out rotary evaporation and recrystallization after the reaction is finished to obtain a solid, and carrying out vacuum drying to obtain the rifamycin B solid. And carrying out suction filtration to obtain a solid, and drying to obtain rifamycin O. The electrochemical oxidation method is mild in condition, green, free of pollution and high in yield, use of extra oxidizing agents and catalysts is avoided, the solvent can be recycled, and the method is suitable for industrial amplification generation.